Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus FOLFIRI versus placebo plus FOLFIRI in second-line metastatic colorectal cancer
2013-000490-79Phase 3Terminated
- Sponsor
- AB Science
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Masitinib + FOLFIRI with Placebo + FOLFIRI (2 arms). Primary endpoint: Overall survival. Started Jan 2014; status: terminated.
02
Drugs
masitinib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2013-000490-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000490-79.